SB 647 (2026): authorizing the department of insurance to participate in a cooperative procurement group via an intergovernmental agreement for a prescription drug discount program.
Cite this page
Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.
- MLA
- “SB 647 (2026): authorizing the department of insurance to participate in a cooperative procurement group via an intergovernmental agreement for a prescription drug discount program.” Granite Record, https://graniterecord.org/bill/2026/sb647. Accessed 19 Oct. 2026.
- APA
- Granite Record. (n.d.). SB 647 (2026): authorizing the department of insurance to participate in a cooperative procurement group via an intergovernmental agreement for a prescription drug discount program. Retrieved 19 Oct. 2026, from https://graniterecord.org/bill/2026/sb647
- Chicago
- Granite Record. “SB 647 (2026): authorizing the department of insurance to participate in a cooperative procurement group via an intergovernmental agreement for a prescription drug discount program.” Accessed 19 Oct. 2026. https://graniterecord.org/bill/2026/sb647.
- BibTeX
@misc{bill-2026-sb647, title = {SB 647 (2026): authorizing the department of insurance to participate in a cooperative procurement group via an intergovernmental agreement for a prescription drug discount program.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2026/sb647}, note = {Accessed 19 Oct. 2026} }
SB 647 (2026)
authorizing the department of insurance to participate in a cooperative procurement group via an intergovernmental agreement for a prescription drug discount program.
- Status: Referred for interim study
- Term: 2025-2026
- House committee: Commerce and Consumer Affairs
- Senate committee: Health and Human Services
- Subject: Public and Mental Health
The Story
It was introduced on January 7, 2026 and referred to the Senate Health and Human Services committee. The committee held a public hearing on March 11, 2026. The committee voted unanimously, 5–0, to recommend that the Senate pass it. On March 26, 2026 the Senate voted to pass it on a voice vote and ordered it to a third reading. It crossed to the House on March 26, 2026 and was referred to the House Commerce and Consumer Affairs committee. The committee held a public hearing on April 15, 2026, with 161 people signed in online: 160 in support and 1 in opposition. The committee held a work session on April 22, 2026. The committee met in executive session on April 29, 2026 to vote on its recommendation. The committee voted unanimously, 15–0, to recommend that the House study it after the session ends, and the report was placed on the consent calendar. On May 14, 2026 the House voted to study it after the session ends on a voice vote. The committee held a work session on September 9, 2026. The committee met in executive session on October 14, 2026 to vote on its recommendation.
Sponsors
- Sen. David Rochefort (R - SD1) (prime sponsor)
- Sen. Kevin Avard (R - SD12)
- Sen. Regina Birdsell (R - SD19)
- Sen. Suzanne Prentiss (D - SD5)
- Sen. Tara Reardon (D - SD15)
- Sen. Cindy Rosenwald (D - SD13)
Hearings and Sessions
- March 11, 2026, 9:15 AM: hearing, Senate Health and Human Services, SH 100
- March 26, 2026: floor debate, Senate
- April 15, 2026, 2:15 PM: public hearing, House Commerce and Consumer Affairs, GP 229
- April 22, 2026, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, GP 229
- April 29, 2026, 10:00 AM: executive session, House Commerce and Consumer Affairs, GP 229
- May 14, 2026: consent calendar, House
- September 9, 2026, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, GP 229
- October 14, 2026, 10:00 AM: executive session, House Commerce and Consumer Affairs, GP 229
Votes
- March 26, 2026, Senate: Ought to Pass — voice vote, passed
- May 14, 2026, House: Refer for Interim Study — voice vote, passed
The Docket
- January 7, 2026: Introduced 01/07/2026 and Referred to Health and Human Services
- March 11, 2026: Hearing: 03/11/2026, Room 100, SH, 09:15 am
- March 26, 2026: Committee Report: Ought to Pass, 03/26/2026, Vote 5-0
- March 26, 2026: Ought to Pass: MA, VV; OT3rdg; 03/26/2026
- March 26, 2026: Introduced (in recess of) 03/26/2026 and referred to Commerce and Consumer Affairs
- April 15, 2026: Public Hearing: 04/15/2026 02:15 pm GP 229
- April 22, 2026: Subcommittee Work Session: 04/22/2026 10:00 am GP 229
- April 29, 2026: Executive Session: 04/29/2026 10:00 am GP 229
- April 29, 2026: Committee Report: Refer for Interim Study 04/29/2026 (Vote 15-0; CC)
- May 14, 2026: Refer for Interim Study: MA VV 05/14/2026
- September 9, 2026: Subcommittee Work Session: 09/09/2026 10:00 am GP 229
- October 14, 2026: Executive Session: 10/14/2026 10:00 am GP 229